All In MedTech

FDA Clearance Tracker · P040024-S099

Restylane Lyft with Lidocaine

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 18, 2018 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 18, 2018

Approved

Time to decision

262 days

Received Aug 29, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P040024-S099
Device name
Restylane Lyft with Lidocaine
Applicant
Q-Med AB
Applicant location
Uppsala
Received
Aug 29, 2017
Decided
May 18, 2018
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P040024

Device type

Device class
Class III

Every decision under product code PKY

FDA's approval statement

As written in FDA's record.

Approval for the Restylane Lyft with Lidocaine for expanding the indications to include injection into the subcutaneous plane in the dorsal hand to correct volume deficit in patients over the age of 21

Source documents

Other decisions for Q-Med AB

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.